Therapy Areas: Cardiovascular
US FDA grants orphan drug designation for Lundbeck's asedebart
11 September 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B), which focuses on brain health, said on Friday it has received US Food and Drug Administration orphan drug designatio...
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
10 September 2026 - Seismic Pharmaceuticals, a biotechnology company focused on advancing novel treatments for heart failure, announced on Wednesday the enrolment of the first patient in its global Ph...
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pela...
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royal...
Lilly to acquire Merida Biosciences in USD2.875bn deal
31 August 2026 - US pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Monday announced that it has agreed to acquire Merida Biosciences, Inc., a biotechnology business developing precision b...
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
28 August 2026 - Medical technology company GE HealthCare (Nasdaq:GEHC) on Friday unveiled three additions to its Vivid cardiovascular ultrasound portfolio: Vivid Explorer, Vivid Advanced and Vivid Fo...